Evommune Inc (EVMN)
Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases in the United States. Its research programs are centered on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company’s pipeline includes EVO756, which is being studied for CSU and AD, and EVO301, which is being developed for AD and UC. Founded in 2020 and based in Palo Alto, California, Evommune trades as common stock on the NYSE under the symbol EVMN.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-EVMN
|
$12
|
24.3% Upside
|
Undervalued
|
$24.13
|
150.0% Upside
|
Bargain
|
Fair
|
0.0%
|
December 10, 2026
|
1.3x
|
35.0x
|
350.2 M
|
70.841 M
|
2.5%
|
54.8%
|
6.8
|
78.9%
|
